title: Biliopancreatic diversion with duodenal switch modifies plasma chemerin in early and late post-operative periods.
abstract: OBJECTIVE
  Bariatric surgery remains the most effective treatment for obesity and metabolic syndrome. Surgical benefit arises from early-phase resolution of hyperglycemia and late-phase weight loss. The adipokine chemerin is of interest given its roles in immunity, adipogenesis, and metabolism. The study objective was to examine the effects of biliopancreatic diversion with duodenal switch (BPD-DS) on plasma chemerin in the early and late post-operative stages.
  
  
  METHODS
  83 adults with obesity undergoing BPD-DS, 45 obese non-surgical controls, and 9 lean surgical controls were enrolled. Plasma parameters and anthropometric measures were obtained at baseline and at, early (24 h, 5 D) and late (6 months and 12 months) post-operative stages.
  
  
  RESULTS
  Plasma chemerin dropped from 176±49 ng/mL at baseline to 132±52 ng/mL 24 h after BPD-DS, rebounded to 200±66 ng/mL after 5 D, and declined to 124±51 and 110±34 ng/mL after 6 and 12 months. Plasma chemerin correlated negatively with measures of inflammation and hepatic injury and positively with measures of obesity, metabolic syndrome, and inflammation in the early and late post-operative periods, respectively.
  
  
  CONCLUSIONS
  Chemerin has a novel role in surgical injury but not hyperglycemia resolution early after BPD-DS. Over the long term, plasma chemerin declines to a new set point that is partially determined by body fat reductions.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Sebastian D
authors.initials: SD
authors.lastname: Parlee
authors.affiliation: College of Pharmacy, Faculty of Health Professions, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Québec, Canada.|Faculté de Pharmacie, Université Laval, Québec, Canada.
authors.forename: Paul
authors.initials: P
authors.lastname: Poirier
authors.affiliation: Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Québec, Canada.
authors.forename: Marc
authors.initials: M
authors.lastname: Lapointe
authors.affiliation: Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Québec, Canada.|Faculté de Pharmacie, Université Laval, Québec, Canada.|Faculty of Health Sciences, University of Ottawa, Ontario, Canada.
authors.forename: Julie
authors.initials: J
authors.lastname: Martin
authors.affiliation: Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Québec, Canada.|Faculté de Pharmacie, Université Laval, Québec, Canada.
authors.forename: Marjorie
authors.initials: M
authors.lastname: Bastien
authors.affiliation: Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Québec, Canada.|Faculté de Médecine, Université Laval, Québec, Canada.
authors.forename: Katherine
authors.initials: K
authors.lastname: Cianflone
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.|College of Pharmacy, Faculty of Health Professions, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Kerry B
authors.initials: KB
authors.lastname: Goralski
mesh_terms: D000328:Adult; D050110:Bariatric Surgery; D015904:Biliopancreatic Diversion; D015992:Body Mass Index; D018925:Chemokines / Q000378:metabolism*; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000378:metabolism* / Q000601:surgery*; D011184:Postoperative Period; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018925:Chemokines; D036341:Intercellular Signaling Peptides and Proteins; C478630:RARRES2 protein, human